SCHEMBL2977489

SCHEMBL2977489

CNC(=O)CN(C(=O)O)C1CCN(CCOc2ccc(Cl)cc2Cl)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
KDM1A O60341 2/20 0.49
OPRM1 P35372 4/20 0.48
OPRD1 P41143 4/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KCNA5 P22460 1/20 0.46
LMNA P02545 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
NPY1R P25929 1/20 0.44
TSHR P16473 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2980105 0.86 SIGMAR1 (0.54) KCNA5MEN1KMT2AALDH1A1
SCHEMBL2973367 0.78 OPRM1 (0.58) OPRM1
SCHEMBL13037097 0.78 KDM1A (0.51) KDM4EKDM1AOPRM1OPRD1CYP1A2
SCHEMBL2982171 0.78 HTR2A (0.52) OPRM1
SCHEMBL2982101 0.77 DCUN1D1 (0.42)
SCHEMBL3600901 0.77 KDM1A (0.61) KDM4EKDM1AOPRM1OPRD1CYP1A2
SCHEMBL2973375 0.77 CHRM2 (0.53) OPRM1MEN1KMT2AALDH1A1HTT
SCHEMBL2975704 0.76 C5AR1 (0.59) OPRM1
SCHEMBL22065929 0.75 CYP1A2 (0.80) KDM4EKDM1ACYP1A2CYP2D6CYP2C9
SCHEMBL2972051 0.74 DRD2 (0.44) OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781590-B2 Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors SANOFI-AVENTIS (FR) 2010-08-24 US disclosed
US-20070021403-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021403-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 KDM4E 1997/4885KDM1A 1930/4885OPRM1 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.